Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-Current DebtOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Depreciation and Depletion: 2020-2025

Historic Depreciation and Depletion for Legend Biotech (LEGN) over the last 5 years, with Sep 2025 value amounting to $2.1 million.

  • Legend Biotech's Depreciation and Depletion fell 9.87% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.5 million, marking a year-over-year decrease of 11.49%. This contributed to the annual value of $10.7 million for FY2024, which is 0.04% down from last year.
  • Legend Biotech's Depreciation and Depletion amounted to $2.1 million in Q3 2025, which was down 6.00% from $2.3 million recorded in Q2 2025.
  • Over the past 5 years, Legend Biotech's Depreciation and Depletion peaked at $3.2 million during Q1 2022, and registered a low of -$20,000 during Q4 2021.
  • For the 3-year period, Legend Biotech's Depreciation and Depletion averaged around $2.6 million, with its median value being $2.7 million (2023).
  • The largest annual percentage gain for Legend Biotech's Depreciation and Depletion in the last 5 years was 12,505.00% (2022), contrasted with its biggest fall of 38.93% (2022).
  • Over the past 5 years, Legend Biotech's Depreciation and Depletion (Quarterly) stood at -$20,000 in 2021, then spiked by 12,505.00% to $2.5 million in 2022, then increased by 9.88% to $2.7 million in 2023, then rose by 0.62% to $2.7 million in 2024, then dropped by 9.87% to $2.1 million in 2025.
  • Its last three reported values are $2.1 million in Q3 2025, $2.3 million for Q2 2025, and $2.3 million during Q1 2025.